A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 3/3/2019 |
| Start Date: | November 2013 |
| End Date: | October 2015 |
Evaluation of the Effects of Insulin Peglispro (LY2605541) on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each
period, participants will receive once daily injections of stable dose LY2605541 or insulin
glargine for 28 to 35 days followed by procedures to look at how the body uses or stores fats
and sugars. Participants will continue to use meal time insulin throughout the study. Healthy
participants will also enroll in the study. They will not receive any study medication.
period, participants will receive once daily injections of stable dose LY2605541 or insulin
glargine for 28 to 35 days followed by procedures to look at how the body uses or stores fats
and sugars. Participants will continue to use meal time insulin throughout the study. Healthy
participants will also enroll in the study. They will not receive any study medication.
Inclusion Criteria:
Type 1 Diabetics:
- T1DM for more than 1 year with Hemoglobin A1c (HbA1c) of less than 9.5%
All Participants:
- Otherwise fit and healthy
- Non smoker
Exclusion Criteria:
Type 1 Diabetics:
- Taking medication or supplements other than insulin to control diabetes
- Suffered a hypoglycemic event in the last 12 months that required hospitalization or
have poor awareness of hypoglycemia
All Participants:
- Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic
corticosteroids
We found this trial at
1
site
Click here to add this to my saved trials
